International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Therapeutic Drug Monitoring

• Publication date

  2002-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/00007691-200202000-00011PMID 11805724
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• C2 Monitoring Strategy for Optimising Cyclosporin Immunosuppression from the Neoral® Formulation

  2012cited by this paper
• Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.

  2001cited by this paper
• Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model.

  2001cited by this paper
• ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.

  2001cited by this paper
• THE EFFECT OF GUT METABOLISM ON TACROLIMUS BIOAVAILABILITY IN RENALTRANSPLANT RECIPIENTS1,2

  2001cited by this paper
• SIROLIMUS ALLOWS EARLY CYCLOSPORINE WITHDRAWAL IN RENAL TRANSPLANTATION RESULTING IN IMPROVED RENAL FUNCTION AND LOWER BLOOD PRESSURE1,2,10

  2001cited by this paper
• From Beach to Bedside: History of the Development of Sirolimus

  2001cited by this paper
• Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post‐transplant year: Pharmacokinetics, exposure‐response relationships, and influence on cyclosporine

  2001cited by this paper
• Failure of Traditional Trough Levels to Predict Tacrolimus Concentrations

  2001cited by this paper
• Median effect analysis of efficacy versus adverse effects of immunosuppressants

  2001cited by this paper
• Comparison of the Effects of Tacrolimus and Cyclosporine on the Pharmacokinetics of Mycophenolic Acid

  2001cited by this paper
• Clinical Utility of Monitoring Tacrolimus Blood Concentrations in Liver Transplant Patients

  2001cited by this paper
• Quantification of mycophenolic acid in plasma samples collected during and immediately after intravenous administration of mycophenolate mofetil.

  2001influential reference
• Limited Sampling Strategies for Estimating Cyclosporin Area Under the Concentration–Time Curve: Review of Current Algorithms

  2001cited by this paper
• Sirolimus Allows Early Cyclosporine Withdrawal in Renal Transplantation Resulting in Improved Renal Function and Lower Blood Pressure.

  2001cited by this paper
• The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups

  2001cited by this paper
• Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable Discussion

  2001influential reference
• Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation.

  2001cited by this paper
• Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living‐donor liver transplantation

  2001cited by this paper
• New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine.

  2001cited by this paper
• Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography--tandem mass-spectrometry.

  2001cited by this paper
• Cyclosporin Measurement – who cares about inaccuracy?

  2001cited by this paper
• Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection.

  2000cited by this paper
• Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation : Implications for therapeutic drug monitoring

  2000cited by this paper
• Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.

  2000influential reference
• Stability of sirolimus (rapamycin) in whole blood.

  2000cited by this paper
• Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

  2000cited by this paper
• Sirolimus-tacrolimus combination immunosuppression.

  2000cited by this paper
• Safety And Efficacy Of Tacrolimus In Combination With Mycophenolate Mofetil (mmf) In Cadaveric Renal Transplant Recipients1

  2000cited by this paper
• Pharmacological surrogates of allograft outcome.

  2000cited by this paper
• New approaches to cyclosporine monitoring raise further concerns about analytical techniques.

  2000influential reference
• A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection.

  2000cited by this paper
• Mycophenolic acid concentrations are associated with cardiac allograft rejection.

  2000cited by this paper
• Proficiency-testing issues relating to sirolimus.

  2000cited by this paper
• Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients.

  2000cited by this paper
• Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.

  2000cited by this paper
• Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring.

  2000cited by this paper
• Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity

  2000cited by this paper
• Evaluation of Limited Sampling Strategies for Estimation of 12-Hour Mycophenolic Acid Area Under the Plasma Concentration–Time Curve in Adult Renal Transplant Patients

  2000cited by this paper
• An immunoassay for the measurement of sirolimus.

  2000cited by this paper
• Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.

  2000cited by this paper
• Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.

  2000cited by this paper
• Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?

  2000influential reference
• Comparison of tacrolimus concentrations measured by the IMx tacrolimus II vs the PRO-TRAC II FK506 ELISA assays.

  1999cited by this paper
• Newer immunosuppressive drugs: a review.

  1999cited by this paper
• Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific?

  1999cited by this paper
• Current opinions on therapeutic drug monitoring of immunosuppressive drugs.

  1999cited by this paper
• Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.

  1999cited by this paper
• The Effect of Renal Insufficiency on Mycophenolic Acid Protein Binding

  1999cited by this paper
• Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil.

  1999cited by this paper
• Stability of mycophenolic acid and mycophenolic acid glucuronide in human plasma.

  1999cited by this paper
• Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite.

  1999influential reference
• The temporal profile of calcineurin inhibition by cyclosporine in vivo.

  1999cited by this paper
• THE INTERNATIONAL MYCOPHENOLIC ACID PROFICIENCY TESTING SCHEME

  1999cited by this paper
• Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

  1998cited by this paper
• The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent

  1998cited by this paper
• Clinical Pharmacokinetics of Mycophenolate Mofetil

  1998cited by this paper
• Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay.

  1998cited by this paper
• The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

  1998cited by this paper
• Therapeutic monitoring of mycophenolic acid: A consensus panel report

  1998cited by this paper
• Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC.

  1998cited by this paper
• Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid.

  1998cited by this paper
• THERAPEUTIC DRUG MONITORING OF CYCLOSPORINE AND TACROLIMUS

  1998cited by this paper
• Therapeutic monitoring of mycophenolic acid. A consensus panel report.

  1998cited by this paper
• Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus.

  1998cited by this paper
• Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine.

  1998cited by this paper
• A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

  1998cited by this paper
• [Not Available].

  1997cited by this paper
• Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration

  1997cited by this paper
• Pitfalls in monitoring tacrolimus (FK 506).

  1997cited by this paper
• Monitoring New Immunosuppressive Agents Are the Methods Adequate?

  1997cited by this paper
• Consensus Guidelines for Therapeutic Drug Monitoring of Rapamycin: Report of the Consensus Panel

  1995cited by this paper
• Sandimmun neoral pharmacokinetics: impact of the new oral formulation.

  1995cited by this paper
• Consensus Document: Therapeutic Monitoring of Tacrolimus (FK‐506)

  1995cited by this paper
• Consensus document: therapeutic monitoring of tacrolimus (FK-506).

  1995cited by this paper
• Lake Louise Consensus Conference on Cyclosporin Monitoring in Organ Transplantation: Report of the Consensus Panel

  1995cited by this paper
• Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics.

  1995cited by this paper
• Concentration-Controlled Trials

  1995cited by this paper
• Mycophenolate Mofetil: A Report of the Consensus Panel

  1995cited by this paper
• Methodological and Clinical Aspects of Cyclosporin Monitoring: Report of the Association of Clinical Biochemists Task Force

  1994cited by this paper
• Cyclosporin A Monitoring in Australia: Consensus Recommendations

  1994cited by this paper
• Reference Methods as a Basis for Accurate Measuring Systems

  1991cited by this paper
• Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine.

  1990cited by this paper
• Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel.

  1990cited by this paper

• Evaluating the Quality of Guidelines Using the AGREE II Tool by a Large Language Model vs Human Appraisers

  2025cites this paper
• The measurement of immunosuppressive drugs bymass spectrometry and immunoassay in a SouthAfrican transplant setting

  2024cites this paper
• Status and Quality of Guidelines for Therapeutic Drug Monitoring Based on AGREE II Instrument

  2023cites this paper
• Pharmacokinetic Model Based on Stochastic Simulation and Estimation for Therapeutic Drug Monitoring of Tacrolimus in Korean Adult Transplant Recipients

  2022cites this paper
• Efficacy, Safety, and Practicality of Tacrolimus Monitoring after Bone Marrow Transplant: Assessment of a Change in Practice.

  2020cites this paper
• Quality of therapeutic drug monitoring (TDM) guidelines is suboptimal: an evaluation using the AGREE II instrument.

  2020cites this paper
• Assessing immunosuppressive drug concentrations in clinical practice

  2020cites this paper
• Determination of sirolimus in blood by high-performance liquid chromatography with ultraviolet detection - Experience and review

  2020cites this paper
• Pharmacogenomics in Therapeutic Drug Monitoring

  2020cites this paper
• Pharmacogenomics in Precision Medicine: From a Perspective of Ethnic Differences

  2020cites this paper
• A Nucleic Acid Nanostructure Built through On-electrode Ligation for Electrochemical Detection of a Broad Range of Analytes.

  2019cites this paper
• Effects on Pharmacokinetics of Tacrolimus in Liver Transplant Patients

  2017cites this paper
• Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region

  2017cites this paper
• Cognitive Evaluation in Liver Transplant Patients Under Calcineurin Inhibitor Maintenance Therapy

  2017cites this paper
• THERAPEUTIC DRUG MONITORING (TDM)

  2017cites this paper
• Assessment of the Measurement Error in Cyclosporine Levels Drawn Between Peripheral and Central Sources

  2017influential citation
• Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches

  2016cites this paper
• Falsely Elevated Tacrolimus Concentrations Using Chemiluminescence Microparticle Immunoassay in Kidney Transplant Patient

  2016cites this paper
• Application of liquid chromatography combined with mass spectrometry or tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants

  2016cites this paper
• Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee

  2016cites this paper
• Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS.

  2015cites this paper
• Untersuchungen zur Pharmakokinetik und Pharmakodynamik von Mycophenolatmofetil im ersten Jahr nach Nierentransplantation

  2015cites this paper
• False Increase in Whole Blood Tacrolimus Levels due to Interference in an Antibody-Conjugated Magnetic Immunoassay Method

  2015cites this paper
• Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs

  2015cites this paper
• Immunosuppression for Kidney Transplantation

  2014cites this paper
• Therapeutic drug monitoring: An overview of commonly monitored drugs

  2014cites this paper
• Delayed false elevation of circulating tacrolimus concentrations after cord blood transplantation in a patient with myelodysplastic syndrome.

  2014cites this paper
• Liquid chromatography-tandem mass spectrometry method as the golden standard for therapeutic drug monitoring in renal transplant.

  2013cites this paper
• Chromatography Separation Techniques Therapeutic Drug Monitoring ( TDM ) in Renal Transplant ( RT ) : Reasons to Choose the LC-MS / MS Method

  2012cites this paper
• Therapeutic Drugs and Their Management

  2012cites this paper
• Therapeutic Drug Monitoring (TDM) in Renal Transplant (RT): Reasons to Choose the LC-MS/MS Method

  2012cites this paper
• Falsely elevated tacrolimus concentrations measured using the ACMIA method due to circulating endogenous antibodies in a kidney transplant recipient.

  2011cites this paper
• Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients

  2011influential citation
• Estimation of Abbreviated Cyclosporine A Area under the Concentration-Time Curve in Allogenic Stem Cell Transplantation after Oral Administration

  2011cites this paper
• Population pharmacokinetics of tacrolimus in kidney transplant patients.

  2010cites this paper
• Immunsuppressiva-Medikamentenspiegelmessung – reine Routine? / Immunosuppressant drug monitoring: a routine undertaking?

  2010cites this paper
• Prediction of Intravenous Cyclosporine Area Under the Concentration–Time Curve After Allogeneic Stem Cell Transplantation

  2010cites this paper
• Immunosuppressant drug monitoring – a routine undertaking? 1

  2010cites this paper
• HPLC-MS/MS Analyse von Immunsuppressiva direkt in Vollblut

  2010cites this paper
• Individualized Neoral doses in pediatric renal transplantation.

  2010cites this paper
• Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice.

  2009cites this paper
• Rheumatoid Factor Interference in a Tacrolimus Immunoassay

  2009cites this paper
• Overview of Therapeutic Drug Monitoring

  2009cites this paper
• Falsely elevated whole blood tacrolimus concentrations due to interference in an affinity column-mediated immunoassay method on Xpand dimension.

  2009cites this paper
• Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact or Fiction?

  2008cites this paper
• Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients

  2007cites this paper
• Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation.

  2007cites this paper
• Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients.

  2007cites this paper
• Predicted influence of sample hematocrit on injected mass of internal standard in mass spectrometry assays utilizing simple protein precipitation for sample preparation

  2007cites this paper
• A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue.

  2007cites this paper
• Validation of limited sampling models (LSM) for estimating AUC in therapeutic drug monitoring--is a separate validation group required?

  2007cites this paper
• Therapeutic drug monitoring of tacrolimus in pancreas transplantation at São Lucas Hospital

  2007cites this paper
• Correlations between calcineurin phosphatase inhibition and cyclosporine metabolites concentrations in kidney transplant recipients: implications for immunoassays.

  2006cites this paper
• Optimizing the use of cyclosporin in allogeneic stem cell transplantation

  2006cites this paper
• Determination of cyclosporine A in whole blood: comparison of a chromatographic method with three different immunological methods.

  2006cites this paper
• Drug monographs on drugs which are frequently analysed in the context of Therapeutic Drug Monitoring / Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden

  2006cites this paper
• Mycophenolate: better value through monitoring?

  2006cites this paper
• Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.

  2006cites this paper
• Sirolimus: the evidence for clinical pharmacokinetic monitoring.

  2005cites this paper
• Cost-Effectiveness of Therapeutic Drug Monitoring: A Systematic Review

  2005cites this paper
• Hematocrit Influences Immunoassay Performance for the Measurement of Tacrolimus in Whole Blood

  2005cites this paper
• Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance

  2005cites this paper
• Immunosuppressant Drug Monitoring: Is the Laboratory Meeting Clinical Expectations?

  2005cites this paper
• Clinical significance of hematocrit interference in the tacrolimus II microparticle enzyme immunoassay: a tentative approach.

  2005cites this paper
• Effects of Hematocrit Value on Microparticle Enzyme Immunoassay of Tacrolimus Concentration in Therapeutic Drug Monitoring

  2005cites this paper
• A micellar electrokinetic capillary chromatography method for monitoring mycophenolic acid in serum of transplant recipients.

  2005cites this paper
• The Rationale for and Limitations of Therapeutic Drug Monitoring for Mycophenolate Mofetil in Transplantation

  2005cites this paper
• Immunosuppressive drug monitoring – what to use in clinical practice today to improve renal graft outcome

  2005cites this paper
• Clinical use of immunosuppressants

  2005cites this paper
• Monographies on drugs, which are frequently analysed in the course of Therapeutic Drug Monitoring Monographien über Medikamente, die regelmässig im Rahmen des Therapeutic Drug Monitorings analysiert werden

  2005cites this paper
• Therapeutic Drug Monitoring of Tacrolimus

  2005cites this paper
• Second-trimester maternal serum invasive trophoblast antigen: a marker for Down syndrome screening.

  2004cites this paper
• Experience with cyclosporine.

  2004cites this paper
• Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry.

  2004influential citation
• Monitoring Cyclosporine of Pre-dose and Post-dose Samples Using Nonextraction Homogeneous Immunoassay

  2004cites this paper
• The EMIT 2000 tacrolimus assay: an application protocol for the Beckman Synchron LX20 PRO analyzer.

  2004cites this paper
• Pre‐Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal Transplantation

  2004cites this paper
• Monitoring Immunosuppressive Drugs: Has It a Future?

  2004cites this paper
• Specimen dilution for C2 monitoring with the Abbott TDxFLx cyclosporine monoclonal whole blood assay.

  2004cites this paper
• [Cylosporine posological individualization strategies in renal transplant patients].

  2004cites this paper
• Analytic Aspects of Cyclosporine Monitoring, on Behalf of the IFCC/IATDMCT Joint Working Group

  2004cites this paper
• Therapeutic drug monitoring of cyclosporine.

  2004cites this paper
• Therapeutic monitoring of immunosuppressant drugs. Where are we?

  2004cites this paper
• Chapter 11 – Monitoring immunosuppressive drugs

  2004cites this paper
• The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration.

  2003cites this paper
• Tacrolimus measurement by microparticle enzyme immunoassay II.

  2003cites this paper
• Therapeutic monitoring of sirolimus: its contribution to optimal prescription.

  2003cites this paper
• [Therapeutic drug monitoring of mycophenolate mofetil, sirolimus and cyclosporine at C2].

  2003cites this paper
• Cyclosporin therapeutic drug monitoring--an established service revisited.

  2003cites this paper
• Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study.

  2003cites this paper
• The Pharmacogenetics of Immunosuppression for Organ Transplantation

  2003cites this paper
• Cyclosporin Monitoring in Australasia: 2002 Update of Consensus Guidelines

  2002cites this paper
• Therapeutic drug monitoring

  2002cites this paper
• IMx tacrolimus II assay: is it reliable at low blood concentrations? A comparison with tandem MS/MS.

  2002cites this paper
• Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation

  2002cites this paper
• The equation proposed by Dr

  year unknowncites this paper